Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

d be available by the middle of this year. Once we have reviewed the data from this study, we will decide on our future development plans with microplasmin for the treatment of acute stroke."

About Stroke

Stroke is a cardiovascular disease affecting the blood vessels of the brain. Stroke is caused by a blockage of the blood vessels of the brain, depriving the brain of oxygen, and can result in severe neurological damage and death. After heart diseases and cancer, stroke is the third most frequent cause of death and the leading cause of disability in the Western world. It is estimated that over two million people suffer a stroke annually. Mortality is high with 20% of patients dying, while the majority of the remainder are left permanently disabled.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in late 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-loo
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... September 18, 2014 Leatherwood Plastics ... listed material, to stay competitive in the semiconductor, ... high-performance materials ultimately impact product quality and productivity, ... owner. , Established in 1980 in Lewisville, TX, ... many fabricators have left the business. Much of ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... April 7 Transgenomic, Inc. (OTC Bulletin Board: TBIO), ... completed a licensing option with the Dana-Farber Cancer Institute, ... Cold-PCR. This variation of the standard PCR technology ... was invented at Dana-Farber by Dr. Mike Makrigiorgos who ...
... WellGen, Inc. today announced that Dr. Roderick (Roddy) ... Executive Officer. Dr. Carter, 45, takes over ... Chief Executive Officer. Mr. Bertoldi will continue in ... Financial Officer of Amphion Innovations plc (LSE: AMP), a ...
... Inc. today announced that it has secured $38 million ... formation in 2004, the company has raised $92 million ... financing round, which consists of two tranches, was led ... pro rata participation of existing investors Apax Partners, Clarus ...
Cached Biology Technology:Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 2Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 3Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations 4Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc. 2Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc. 3Aerovance Secures $38 Million in Equity Financing 2Aerovance Secures $38 Million in Equity Financing 3
(Date:9/18/2014)... ever starts a "frequent flyers" program, fruit flies surely ... laboratory has hosted increasing numbers of fruit fly research ... station in April, and another is scheduled launch to ... to launch in December. , Fruit flies are biomedical ... in space. Model organisms can reveal the basis for ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... which have devastated algal forests in the eastern Mediterranean ... basin if their distribution continues to expand as the ... an international team of researchers led by Dr Adriana ... the Mediterranean Institute for Advanced Studies in Spain, is ... of the team surveyed more than 1000 kilometres of ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... -- Weill Cornell Medical College and the Columbia University ... Mortimer D. Sackler, M.D. Prize for Distinguished Achievement in ... Dr. Fernando Nottebohm for his seminal work in songbirds ... Dr. Nottebohm is currently the Dorothea L. Leonhardt ...
... but in an infectious disease, it is insidious. Witness tuberculosis, ... before bursting forth into infection. TB,s stealthy nature has made ... to control it. The World Health Organization estimates that a ... a study led by Stanford scientists has provided new insights ...
... sends the human immune system into overdrive it can ... and thrive inside our digestive system. New research suggests ... significant role in triggering the innate immune system to stay ... in the face of an infection. But exactly how ...
Cached Biology News:Sackler Prize awarded to pioneering neuroscientist 2Sackler Prize awarded to pioneering neuroscientist 3Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 2Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 3Tuberculosis strain spread by the fur trade reveals stealthy approach of epidemics 4Stress wrecks intestinal bacteria, could keep immune system on idle 2
... The LabChip 3000 drug discovery system ... cell-based assays. Using LabChip technology, ... in a serial, continuous flow fashion. ... quality of results exceeds what is ...
...
...
...
Biology Products: